<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380325</url>
  </required_header>
  <id_info>
    <org_study_id>Bootcamp1</org_study_id>
    <nct_id>NCT03380325</nct_id>
  </id_info>
  <brief_title>The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes</brief_title>
  <official_title>The Effects of Iloprost Infusion on Capillary Recruitment and Whole-body Glucose Uptake in Type 2 Diabetic Patients - a Cross-over Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <brief_summary>
    <textblock>
      This study examines the effects of iloprost - a stable prostacyclin analogue - on
      insulin-mediated muscle capillary recruitment and whole-body glucose uptake in a cross-over
      design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In type 2 diabetes impaired insulin-mediated muscle perfusion is thought to contribute to
      reduced whole-body glucose uptake. This study aims to identify iloprost - a stable
      prostacyclin analogue - as a possible therapeutic option to increase whole-body glucose
      uptake via enhancement of muscle perfusion.

      All participants will be subjected to two hyperinsulinemic-euglycemic clamps; one with and
      one without simultaneous iloprost infusion in a randomized cross-over design. Microvascular
      blood volume will be measured by means of contrast-enhanced ultrasonography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2016</start_date>
  <completion_date type="Actual">June 29, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of disappearance</measure>
    <time_frame>During the clamp</time_frame>
    <description>Glucose uptake in peripheral tissues during hyperinsulinemic euglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Capillary recruitment</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Change in skeletal muscle microvascular blood volume upon insulin infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Stroke volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous cardiovascular monitoring</measure>
    <time_frame>Before and during the clamp</time_frame>
    <description>Systemic vascular resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Sensitivity/Resistance</condition>
  <arm_group>
    <arm_group_label>Iloprost first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over starts with iloprost intervention, then second clamp without iloprost.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloprost second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over starts without iloprost intervention, then second clamp with iloprost.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost infusion</intervention_name>
    <description>Iloprost is a stable prostacyclin analogue</description>
    <arm_group_label>Iloprost first</arm_group_label>
    <arm_group_label>Iloprost second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Male or female (post-menopausal)

          -  Age above 45 years and below 70 years

          -  BMI &gt;30 kg/m2

          -  HbA1c &lt; 80 mmol/mol or &lt; 8,6% Subjects must use metformin

          -  Stable medication use

          -  Stable tension regulation (with or without medication)

          -  Subjects should be able to give informed consent

        Exclusion Criteria:

          -  A history of cardiovascular event (Cerebrovascular event, myocardial infarction or
             pacemaker implantation)

          -  Severe-very severe lung emphysema (GOLD stage III-IV)

          -  Use of any antibiotics or proton pump inhibitor (PPI) in the past three months

          -  Use of any other antidiabetic medication besides metformin (e.g. SU-derivates,
             insulin)

          -  Use of a platelet inhibitor or cumarin derivate during

          -  Subjects participated in a lifestyle programme in the past 6 months (diet or exercise)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Sern√©, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Erik Serne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Capillary recruitment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

